Efficacy of the herbal medicine Unkei-to as an adjunctive treatment to hormone replacement therapy for postmenopausal women with depressive symptoms

Clinical Neuropharmacology

Volumn 27, Issue 4, 2004, Pages 157-162

  Koike, Koji ^a   Ohno, Satoshi ^a   Takahashi, Noriko ^a,b   Suzuki, Nobutaka ^a   Nozaki, Noriko ^a   Murakami, Kouichi ^a   Sugiura, Kouichi ^c   Yamada, Kiyofumi ^a,b   Inoue, Masaki ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Sugiura Clinic   (Japan)

^c Graduate School of Medical Science ^*

Author keywords

Adjunctive therapy; Herbal medicine; Hormone replacement therapy; Menopausal depression; Unkei to

Indexed keywords

ESTRADIOL; MEDROXYPROGESTERONE ACETATE; TOKISHAKUYAKU SAN; UNKEI TO;

ADULT; AGED; ARTICLE; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; HERBAL MEDICINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE SUBSTITUTION; HUMAN; INVOLUTIONAL DEPRESSION; MENOPAUSAL SYNDROME; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; STATISTICAL ANALYSIS;

AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; DRUGS, CHINESE HERBAL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MANIFEST ANXIETY SCALE; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 4344658205     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000138634.34498.05     Document Type: Article

References (49)

1. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand. 1977;64:1-99.
2. Montgomery JC, Appleby L, Brincat M, et al. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. Lancet. 1987;1:297-299.
3. Ditkoff EC, Crary WG, Cristo M, et al. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991-995.
4. Zweifel JE, O'Brien WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology. 1997;22:189-212.
5. Palinkas LA, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:30-36.
6. Schneider MA, Brotherton PL, Hailes J. The effect of exogenous oestrogens on depressive in menopausal women. Med J Aust. 1977;2:162-163.
7. Cohen IR, Wise PM. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. Endocrinology. 1988;122:2619-2625.
8. Biegon A, Reches A, Snyder L, et al. Serotonergic and noradrenergic receptors in the rat brain: modulation by chronic exposure to ovarian hormone. Life Sci. 1983;32:2015-2021.
9. Luine VN, McEwen BS. Effect of oestradiol on turnover of type A monoamine oxidase in brain. J Neurochem. 1975;28:1221-1227.
10. Avis NE, Brambilla D, McKinlay SM, et al. A longitudinal analysis of the association between menopause and depression: results from the Massachusetts Women's Health Study Ann. Epidemiology. 1994;4:214-220.
11. Hunter M. The South-East England longitudinal study of the climacteric and postmenopause. Maturitas. 1992;14:117-126.
12. Schneider MA, Brotherton PL. Physiological, psychological and situational stress in depression during the climacteric. Maturitas. 1979;1:153-158.
13. Koyama T, Ohara M, Ichimura M, et al. Effect of Japanese Kampomedicine on hypothalamic-pituitary-ovarian function in women with ovarian insufficiency. Am J Chin Med. 1988;16:47-55.
14. Koike K, Zhang ZX, Sakamoto Y, et al. The Herbal medicine Unkei-to stimulates CINC production in the pituitary folliculo-stellate (FS)-like cell line (TtT/GF). Am J Reprod Immunol. 1998;39:249-255.
15. Yasui T, Matsuzaki T, Ogata R, et al. The herbal medicine Unkei-to stimulates the secretion of a cytokine-induced neutrophil chemoattractant, CINC/gro, in the rat ovarian cell culture. Am J Reprod Immunol. 2003;49:14-20.
16. Terawaki K, Koike K, Yuzurihara M, et al. An inhibitory effect of cytokine-induced neutrophil chemoattractant on corticotropin-releasing factor-induced increase in locomotor activity. Brain Res. 2001;917:133-137.
17. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry. 1965;12:63-70.
18. Fukuda K, Kobayashi S. A study on a self-rating depression scale. Seishin Shinkeigaku Zasshi. 1973;75:673-679. In Japanese.
19. Gabrys JB, Peters K. Reliability, discriminant and predictive validity of the Zung's Self-Rating Depression Scale. Psychol Rep. 1985;57:1091-1096.
20. Kitamura T, Shima S, Sugawara M, et al. Temporal variation of self-rating questionnaires: repeated use of the General Health Questionnaire and Zung's Self-Rating Depression Scale among women during antenatal and postnatal periods. Acta Psychiatr Scand. 1994;90:446-450.
21. Nagata M, Nagai Y, Sobajima H, et al. Depression in the mother and maternal attachment: results from a follow-up study at 1 year postpartum. Psychopathology. 2003;36:142-151.
22. Shima S, Shikano T, Kitamura T, et al. New self-rating scales for depression. Clin Psychiatry. 1985;27:717-723. In Japanese.
23. Nakazato K, Mizuguchi T. Development and validity of the Japanese version of the State-Trait Anxiety Inventory. Shinshin-Igaku. 1982;22:107-112.
24. Spielberger CD, Gorsuch RL, Lushene RE. The State-Trait Anxiety Inventory Manual. Palo Alto, CA: Consulting Psychologists Press; 1970.
25. Nakazato K, Shimonaka Y. Japanese version of the State-Trait Anxiety Inventory: age and sex differences. Perceptional Motor Skill. 1989;69:611-617.
26. Legge SD, Piattella MC, Pozzilli C, et al. Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosia. Mult Scler. 2003;9:302-306.
27. Tselebis A, Papaleftheris E. Smoking related to anxiety and depression in Greek medical staff. Psychol Rep. 2003;92:529-532.
28. Hammarback S, Backstrom T, Holst J, et al. Cyclic mood change as in the premenstrual tension syndrome during sequential estrogen-progestagen postmenopausal replacement therapy. Acta Obstet Gynecol Scand. 1985;64:393-397.
29. Bjorn I, Bixo M, Strandberg-Nojd K, et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. Am J Obstet Gynecol. 2000;183:1419-1426.
30. Fava M, Kendler KS. Major depressive disorder. Neuron. 2000;28:335-341.
31. Akiskal HS. Mood disorders: introduction and overview. In: Sadock BJ, Sadock VA, eds. Comprehensive Textbook of Psychiatry. New York: Lippincott, Williams & Wilkins; 2000:1284-1298.
32. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13-25.
33. Sheline YI, Sanghhavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci. 1999;19:5034-5043.
34. Bremner JD, Narayan M, Anderson ER, et al. Hippocampal volume reduction in major depression. Am J Psychiatry. 2000;157:115-118.
35. Arborelius L, Owens MJ, Plotsky PM, et al. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol. 1999;160:1-12.
36. Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222-1227.
37. Reagan LP, McEwen BS. Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. J Chem Neuroanat. 1997;13:149-167.
38. Holsboer F. Stress hypercorticolism and corticosteroid receptors in depression: implications for therapy. J Affect Disord. 62:77-91.
39. Belanoff JK, Flores BH, Kalezhan M, et al. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001;21:516-521.
40. Britton KT, Akwa Y, Spina MG, et al. Neuropeptide Y blocks anxiogenic-like behavioral activation of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides. 2000;21:37-44.
41. Emoto H, Yokoo H, Yoshida M, et al. Corticotropin-releasing factor enhances noradrenaline release in the rat hypothalamus assessed by intracerebral microdialysis. Brain Res. 1993;601:286-288.
42. Kojima Y, Kumazawa Y, Shibukawa N, et al. Screening for interferon inducers and mitogens among various medical plants used in traditional Sino-Japanese medicine. Proc Sympo WAKAN-YAKU. 1980;13:101-103.
43. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22:3251-3261.
44. Singh M, Meyer EM, Simpkins JW. The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rat. Endocrinology. 1995;136:2320-2324.
45. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;228:321-333.
46. Soares CN, Poitras JR, Prouty J, et al. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms. J Clin Psychiatry. 2003;64:473-479.
47. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
48. Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55:406-412.
49. Soares CN, Cohen LS. The perimenopause, depressive disorders, and hormonal variability. Sao Paulo Med J. 2001;119:78-83.